Pneumonia vaccine side effects, day by day
Most people get a sore arm for a day or two and nothing else. In the one trial that put two of these products head to head in adults 50 and older, injection site pain was reported by 39.4% of 1,177 CAPVAXIVE recipients and 51.7% of 1,175 PREVNAR 20 recipients (CAPVAXIVE Prescribing Information, US FDA). In that age group, solicited reactions after CAPVAXIVE lasted a median of 1 day.
Two things move that number: which of the three adult products you got, and whether this is a first pneumococcal dose or a repeat. Every rate below names its product, its denominator and its source.
The pneumonia vaccine is the pneumococcal vaccine
“Pneumonia vaccine” is what people call it. It is not what is in the syringe.
All three US adult products target one bacterium, Streptococcus pneumoniae, and only some strains of it. The PREVNAR 20 pneumonia indication in adults names 20 serotypes and the CAPVAXIVE one names 21, each listed by number (PREVNAR 20 and CAPVAXIVE Prescribing Information, US FDA). PNEUMOVAX 23 states the limit in its own words: it “will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine” (PNEUMOVAX 23 Prescribing Information, Merck).
So none of them covers pneumonia from influenza, from other bacteria, or from pneumococcal strains outside the list. None contains a live organism either. They are made from the capsular sugar coat of the bacterium, alone or linked to a carrier protein, and no label lists pneumonia as a reaction. Our course material covers what is actually in a vaccine.
Which product you got changes the numbers
There is no single pneumococcal reaction rate, because there is no single pneumococcal vaccine.
| Product | Type | Carrier protein | Reactions solicited for |
|---|---|---|---|
| PNEUMOVAX 23 | PPSV23, plain polysaccharide, US approval 1983 | none | 14 days after each dose |
| PREVNAR 20 | PCV20, conjugate, US approval 2021 | CRM197 | 10 days local, 7 days systemic |
| CAPVAXIVE | PCV21, conjugate, US approval 2024 | CRM197 | 5 days |
Sources: the three prescribing information documents named above.
PREVNAR 20 and CAPVAXIVE link their polysaccharides to CRM197, which both labels describe as a non-toxic variant of diphtheria toxin, and both are contraindicated in anyone with a history of severe allergic reaction to diphtheria toxoid. PNEUMOVAX 23 has no carrier protein and no such contraindication. Our pages explain how a conjugate vaccine differs from a plain polysaccharide one.
Read the last column before comparing anything. All three labels warn that rates from one vaccine’s trials cannot be compared directly with another’s. The exception is CAPVAXIVE against PREVNAR 20, randomized head to head.
How common each side effect actually is
PNEUMOVAX 23
In a randomized, double-blind, placebo-controlled crossover trial in adults 50 and older, safety was recorded for 14 days after each injection (PNEUMOVAX 23 Prescribing Information, Merck).
| Reaction, within 14 days | First dose (n=438) | Repeat dose (n=548) | Placebo (n=984) |
|---|---|---|---|
| Pain, soreness or tenderness | 60.0% | 77.2% | 7.7% |
| Swelling or induration | 20.3% | 39.8% | 2.8% |
| Redness | 16.4% | 34.5% | 3.3% |
| Headache | 17.6% | 18.1% | 8.9% |
| Weakness or fatigue | 13.2% | 17.9% | 6.7% |
| Muscle aches | 11.9% | 17.3% | 3.3% |
| Chills | 2.7% | 7.8% | 1.8% |
| Fever | 1.4% | 2.0% | 0.7% |
The repeat dose came about 3 to 5 years after the first. Fever was an unsolicited report here, and the label counts people who felt feverish as well as people with a measured temperature.
The placebo column in that PNEUMOVAX 23 trial is the most useful one in this article. Among 984 people given a saline injection, 7.7% reported arm pain, 8.9% a headache and 6.7% fatigue. Setting a reaction against the rate you would expect anyway is the basis of vaccine safety monitoring. It also shows which symptoms are genuinely the injection: redness was 3.3% on placebo and swelling 2.8%, so a red, puffy arm is the dose.
PREVNAR 20
In Study 1 (NCT03760146), pneumococcal vaccine-naive adults recorded arm symptoms for 10 days and whole-body symptoms for 7 days (PREVNAR 20 Prescribing Information, US FDA).
| Reaction | 18 to 49 (n=335) | 50 to 59 (n=331) | 60 and older (n=1,505) |
|---|---|---|---|
| Any injection site pain | 81.2% | 72.5% | 55.4% |
| Swelling over 3/4 inch | 11.6% | 8.8% | 7.5% |
| Redness over 3/4 inch | 9.0% | 8.2% | 7.3% |
| Muscle pain | 66.6% | 49.8% | 39.1% |
| Fatigue | 42.7% | 39.3% | 30.2% |
| Headache | 38.8% | 32.3% | 21.5% |
| Fever 38.0 C (100.4 F) or higher | 1.2% | 1.5% | 0.9% |
Reactions fall off with age, which surprises most people. PREVNAR 20 injection site pain drops from 81.2% at 18 to 49 down to 55.4% at 60 and older. The comparison arm in that oldest group, 1,483 people given PREVNAR 13 and then PNEUMOVAX 23 a month later, reported any injection site reaction 56.0% of the time against 57.4% for PREVNAR 20.
CAPVAXIVE against PREVNAR 20
Study 1 in the CAPVAXIVE label randomized vaccine-naive adults to one product or the other, and solicited symptoms on days 1 to 5 (CAPVAXIVE Prescribing Information, US FDA).
| Reaction, adults 50 and older | CAPVAXIVE (n=1,177) | PREVNAR 20 (n=1,175) |
|---|---|---|
| Any injection site pain | 39.4% | 51.7% |
| Pain that interfered with activity | 8.7% | 8.7% |
| Pain that prevented daily activity | 0.1% | 0.1% |
| Redness | 5.4% | 6.3% |
| Swelling | 6.0% | 8.3% |
| Fatigue | 20.1% | 19.6% |
| Headache | 11.5% | 12.9% |
| Muscle aches | 5.9% | 6.7% |
| Fever 38.0 C (100.4 F) or higher | 1.3% | 1.3% |
Fever percentages use the people with temperature data: 1,169 in the CAPVAXIVE group and 1,170 in the PREVNAR 20 group. The whole gap between the two products is in mild arm pain. Moderate pain, severe pain and fever were the same in both arms.
Pneumonia vaccine side effects day by day, and what “after 1 week” means
| Days after the dose | What the trials recorded |
|---|---|
| Day 1 to 3 | CAPVAXIVE: 86.5% of solicited reactions in adults 50 and older had ended, median 1 day. In adults 18 through 49, 81.3% had ended, median 2 days. |
| Day 1 to 5 | CAPVAXIVE stops asking. PNEUMOVAX 23: injection site reactions “typically resolved by 5 days following vaccination”, and extra painkiller use returned to baseline by day 5. |
| Day 1 to 7 | PREVNAR 20 stops asking about whole-body symptoms. |
| Day 1 to 10 | PREVNAR 20 stops asking about arm symptoms. |
| Day 1 to 14 | PNEUMOVAX 23 stops asking. The longest solicited window of the three. |
| Day 1 to 30 | All three collected anything else a participant chose to report. |
| To 6 months | PREVNAR 20 and CAPVAXIVE followed serious adverse events. |
Sources: the three prescribing information documents named above.
Only two of the three labels publish a duration, and both are short. PREVNAR 20 publishes none for adults. It gives one for infants and one for children up to 17, and neither can be borrowed for a 68-year-old.
So what does a reaction after 1 week mean?
It means you are outside the pattern these trials describe.
No label describes an expected adult reaction still present on day 7. The longest window any of them asks about is 14 days, and the published adult durations inside it are the CAPVAXIVE medians of 1 day and 2 days. The only published tail across the three is a CAPVAXIVE study of children aged 2 to 17, where reactions ran a median of 2 days with a range of 1 to 12 days and 98.2% had ended by day 5. That is a pediatric figure and it is quoted here as one.
Outside the pattern does not mean dangerous. It means no label can tell you it is expected, so ask someone who can examine your arm.
A repeat PNEUMOVAX 23 dose reacts harder than the first
Arm reactions after a second PNEUMOVAX 23 dose were far more common than after a first: pain in 77.2% of 548 revaccinees against 60.0% of 438 first-dose recipients, swelling in 39.8% against 20.3%, redness in 34.5% against 16.4%. The label’s own conclusion reads: “In this clinical study an increased rate of local reactions was observed with revaccination at 3-5 years following initial vaccination.”
The gap is widest in the oldest group. In people 65 and older given PNEUMOVAX 23, any injection site reaction was 79.3% after revaccination against 52.9% after a first dose, and discomfort that interfered with or prevented usual activity, or induration of 4 inches or more, was 30.6% against 10.4%. In people aged 50 to 64 the two rates were close, 79.6% against 72.8%. Whole-body symptoms barely moved: headache was 18.1% after a repeat dose and 17.6% after a first.
That describes what a repeat dose feels like. It is not a reason to have one or to skip one. Which product, at which age, at which interval is a decision for your clinician under national immunization guidance.
What counts as a severe reaction
“Severe” in these trials is a functional threshold, not a medical emergency. All three labels define it the same way: mild does not interfere with activity, moderate interferes with activity, severe prevents daily activity. For redness and swelling they use size, and severe means more than 4 inches across.
By that definition, severe injection site pain was rare: 0.1% of 1,177 CAPVAXIVE recipients and 0.1% of 1,175 PREVNAR 20 recipients aged 50 and older, and 0.2% of 1,505 PREVNAR 20 recipients aged 60 and older in Study 1. It was more common in younger adults, at 1.2% of 331 PREVNAR 20 recipients aged 50 to 59. Someone with a severe reaction by this definition had a bad arm and lost a day. Our course material covers the difference between expected reactions and severe ones.
Rare reactions, and what the labels do not give you
Serious adverse events sat level with the comparison arm in both conjugate programs.
- PREVNAR 20, Studies 1 through 6: 1.5% (67 of 4,552) reported at least one serious adverse event within 6 months, against 1.8% (44 of 2,496) after PREVNAR 13 or another control. Within 1 month both were 0.4%.
- CAPVAXIVE, Studies 1 through 4: 0.3% (14 people) reported one within 1 month, against 0.3% (7) after an active comparator. Across those four studies 4,556 people received CAPVAXIVE. At 6 months the label reports 1.4% (56) against 2.0% (40), and gives the counts but not the denominator for that analysis. Two CAPVAXIVE events were judged vaccine related, and the label names both: one acute allergic reaction of bronchospasm within 30 minutes of the dose, and one injection site cellulitis on day 6 that required hospitalization.
Now the honest limits. Each label lists reactions reported after approval, and the PNEUMOVAX 23 list includes Guillain-Barre syndrome, anaphylactoid reactions and injection site necrosis. Those lists carry no denominator, by design: the reports are voluntary, from a population of uncertain size, so the labels state it is not always possible to estimate their frequency reliably. No incidence rate for anaphylaxis or for Guillain-Barre syndrome appears in any of the three labels, so this page quotes none.
If you are immunocompromised
All three labels flag altered immunocompetence for the same reason: the vaccine may work less well, not that it hurts more. PREVNAR 20 goes further and states that safety and immunogenicity data are not available for immunocompromised groups, and that vaccination should be considered case by case. None of the three reports higher reaction rates in this group. Our course material covers immunizing people with weakened immune systems.
When to call someone
Get emergency care for signs of a severe allergic reaction. These begin soon after the injection, and all three labels require treatment for anaphylaxis to be immediately available where the vaccine is given.
Call your clinician, without rushing, for anything that breaks the pattern above:
- A reaction still getting worse on day 4 or later
- Redness or swelling that keeps spreading, or an area larger than 4 inches across
- Any reaction still present after a week
- Pain that stops you doing normal daily things
- Fever, especially if it starts more than a day or two after the dose
Tell whoever gives the dose if you have fainted after an injection before. The CAPVAXIVE label lists syncope as a specific precaution for injectable vaccines.
How to report a reaction
Report it even if you are not sure the vaccine caused it. That is the point of the system.
In the United States, suspected reactions go to the Vaccine Adverse Event Reporting System, established in 1990 and co-managed by the Centers for Disease Control and Prevention and the Food and Drug Administration. Anyone can report to it, and its site is explicit about what it is for: “VAERS is not designed to determine if a vaccine caused a health problem, but is especially useful for detecting unusual or unexpected patterns of adverse event reporting that might indicate a possible safety problem with a vaccine” (vaers.hhs.gov).
Every postmarketing list above exists because somebody filed a report. Deciding whether a vaccine caused an event is a separate, formal exercise, and not the reporter’s job. Our course covers how vaccine safety surveillance works. Other countries run their own systems, and national guidance takes precedence.
FAQ
Is it normal to still have pneumonia vaccine side effects after 1 week?
It is outside what the labels describe. The published adult durations are a median of 1 day for CAPVAXIVE in people 50 and older, with 86.5% of reactions gone within 3 days, and 2 days in people 18 through 49. PNEUMOVAX 23 injection site reactions typically resolved by 5 days, and PREVNAR 20 publishes no adult duration. A reaction still present at seven days is not covered by any of that, so it is worth a call rather than a wait.
Which pneumonia vaccine has the fewest side effects?
In the only head-to-head trial in these labels, injection site pain was reported by 39.4% of 1,177 CAPVAXIVE recipients and 51.7% of 1,175 PREVNAR 20 recipients aged 50 and older. The difference was in mild pain. Which product you get is a clinical decision about serotype coverage and your own history, not a side effect decision.
Why did my second PNEUMOVAX 23 dose hurt more than the first?
Because that is what the trial found. Pain was reported by 77.2% of 548 people getting a repeat dose 3 to 5 years later, against 60.0% of 438 first-dose recipients and 7.7% of 984 people given a placebo injection (PNEUMOVAX 23 Prescribing Information, Merck).
Can the pneumonia vaccine give me pneumonia?
No. None of the three products contains a live organism. PNEUMOVAX 23 is purified capsular polysaccharide, and PREVNAR 20 and CAPVAXIVE are the same polysaccharide conjugated to the CRM197 carrier protein.
Side effects of other vaccines
We publish the same kind of rate table for other vaccines, taken from the manufacturer’s prescribing information and shown beside the placebo group from the same trial.
- Shingles vaccine side effects covers Shingrix by age band, how long reactions last, and whether the second dose is worse than the first.
- RSV vaccine side effects covers Arexvy, Abrysvo and mResvia in adults, what the trials recorded in pregnancy, and what babies actually receive.
